ArticleRMD open2026
Assessing flares in patients with psoriatic arthritis using questionnaires.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe psoriatic arthritis (PsA) FLARE Questionnaire was developed to study flares in PsA. We aimed to validate the FLARE Questionnaire and compare it with the Psoriatic Arthritis Impact of Disease 12-item Questionnaire (PsAID-12) to determine whether PsAID-12 was sufficient for assessing disease flares.
methodsThis cross-sectional study enrolled 150 patients aged ≥18 years. Data collection using a standard protocol consisted of demographic characteristics, patient-reported outcomes (including PsAID-12), cutaneous/musculoskeletal examination findings, routine labs, FLARE Questionnaire and a stand-alone question asking participants whether they believed they were experiencing a flare. Internal consistency of the FLARE Questionnaire was measured using Cronbach's α. Test-retest reliability was evaluated using the intraclass correlation coefficient (ICC) by administering the questionnaire twice to 51 patients, 1 week apart. Agreement between flare definition using the FLARE Questionnaire and the stand-alone question was determined using Cohen's κ. Associations between clinical features and flares self-reported by the stand-alone question were assessed using logistic regressions. The FLARE Questionnaire and PsAID-12 were compared against the stand-alone question using receiver operating characteristics (ROC) curve analysis.
resultsThe FLARE Questionnaire displayed good internal consistency (α = 0.88, 95% CI 0.85 to 0.90), good test-retest reliability (ICC = 0.76, p<0.001, 95% CI 0.59 to 0.87), and moderate agreement between flare definition using the cut-off and stand-alone question (κ = 0.59, 95% CI 0.45 to 0.72). However, ROC analysis demonstrated that the FLARE Questionnaire (area under the curve (AUC) = 0.90, 95% CI 0.85 to 0.95) and PsAID-12 (AUC = 0.83, 95% CI 0.76 to 0.90) performed similarly. A PsAID-12 cut-off of ≥3.13 achieved the best balance between sensitivity (0.72) and specificity (0.79).
conclusionsPsAID-12 may be used for defining PsA flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.